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Numerous clinical trials have established the value of antiplatelet therapies for acute coronary syndromes
(ACS). Aspirin (ASA), thienopyridines (i.e., clopidogrel and ticlopidine) and GP IIb/IIIa antagonists comprise
the major classes of antiplatelet therapies demonstrated to be of benefit in the treatment of ACS and for the
prevention of thrombotic complications of percutaneous coronary intervention (PCI). Clopidogrel is beneficial
when administered before and after PCI, and is more effective when combined with either ASA or GP IIb/IIIa
inhibitors in preventing post-PCI complications, coronary subacute stent thrombosis, and thrombotic events
in general. It is currently unclear whether a higher loading dose of clopidogrel (600 mg) is better than the
standard loading dose (300 mg), how long therapy should continue, and which maintenance dose is optimal.
The role of the GP IIb/IIIa antagonists in ACS is less clear due to conflicting data from several studies with
different patient populations. Currently, it appears that the use of GP IIb/IIIa antagonists might be most
beneficial in high-risk ACS patients scheduled to undergo PCI, who demonstrate non-ST-segment elevation
myocardial infarction and elevated troponin levels.
Key words: catheterization/diagnostic interventional>cardiac, acute coronary syndromes>ischemic heart
disease, platelets, thrombosis/hypercoagulable
Introduction
Acute coronary syndromes, one manifestation of atheroth-
rombosis, include unstable angina (UA), non-ST-segment
elevation myocardial infarction (NSTEMI), and ST-segment
elevation myocardial infarction (STEMI).1 Large-scale clin-
ical trials have established the relative value of anticoag-
ulant and/or antiplatelet therapies for a number of condi-
tions characterized by arterial thromboses including ACS,
ischemic stroke (IS), and established peripheral artery dis-
ease (PAD). Aspirin was the first recognized antiplatelet
drug based on its ability to inhibit cyclooxygenase (COX)-1
enzymatic activity. Thienopyridines (i.e., clopidogrel and
ticlopidine), ASA, and GP IIb/IIIa antagonists are the major
classes of antiplatelet therapies found to be beneficial in the
treatment of ACS, and for prevention of thrombotic complica-
tions in patients managed with PCI. The ACC/AHA practice
guidelines recommend antiplatelet therapy as a cornerstone
of ACS management.2 In this article, a review of landmark
trials is undertaken, which establishes how contemporary
antiplatelet therapies are used in patients with ACS.
Establishing the Benefit of Clopidogrel in Acute Coronary
Syndrome Risk Reduction
The active metabolite of clopidogrel inhibits platelet activa-
tion by noncompetitively inhibiting the binding of adenosine
diphosphate (ADP) to the P2Y12 receptor (ADP-receptor
antagonist) that participates in the activation of the GP
IIb/IIIa complex. Inhibition of platelet activation via the
P2Y12 signaling pathway leads to reduced activation of the
GP IIb/IIIa complex and thus blocks aggregation. Interfer-
ence with this specific ADP-dependent step in the platelet
activation pathway also restricts platelet activation by some
other agonists, resulting in a further decrease in platelet
recruitment and aggregation.3
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Figure 1: The CURE trial. Cumulative hazard rates for the first primary
outcome (death from cardiovascular causes, nonfatal MI, or stroke)
during the 12 months of the study. The results demonstrate the sustained
effects of clopidogrel. Reproduced with permission from Yusuf S et al.5
The benefits of clopidogrel were established by Clopido-
grel versus Aspirin in Patients at Risk of Ischemic Events
(CAPRIE) and Clopidogrel in Unstable angina to prevent
Recurrent Events (CURE), two landmark pivotal trials that
enrolled more than 31,000 patients at risk for recurrent
atherothrombotic events.4,5
Clopidogrel versus Aspirin: The CAPRIE study evaluated
19,185 patients with atherosclerotic vascular disease, includ-
ing recent myocardial infarction (MI) (with either enzyme
elevation or new Q-waves on electrocardiogram [ECG]),
recent IS, or established PAD.4 The primary outcome was
a composite endpoint of IS, MI, or vascular death. Patients
treated with clopidogrel had an annual 5.32% risk of IS,
MI, or vascular death compared with 5.83% with ASA (8.7%
relative risk reduction [RR] versus ASA; p = 0.0431).
Establishing the Benefit of Dual Antiplatelet Therapy
The CURE study randomized patients with UA or NSTEMI
presenting within 24 hours of symptom onset to receive
either clopidogrel 300 mg loading dose (followed by
clopidogrel 75 mg/day) plus ASA 75 mg to 325 mg/day,
or placebo plus ASA.5 The composite primary endpoint
(cardiovascular [CV] death, MI, or stroke) was reduced by
20% (p<0.001) in patients who received dual antiplatelet
therapy, with a clear and significant reduction in the
risk of the composite endpoint that emerged by 24 h
after randomization; the absolute event rate was 9.3% in
the clopidogrel group and 11.4% in the placebo group
(Figures 1 and 2).5 The CURE study investigated medically
managed patients (n = 7, 985) as well as those who received
PCI (PTCA) and/or coronary artery bypass graft (CABG)
(n = 4, 577). The benefit of adding clopidogrel to ASA was
consistent in these subgroups as well. An increase in major
and minor bleeding was observed in clopidogrel-treated
patients; however, no significant increase in life-threatening
bleeding was noted. No excess major bleeding was observed
within 7 days of surgery in patients who had clopidogrel
discontinued a median of 5 days prior to their procedure.
Accordingly, if elective CABG is planned, clopidogrel should




































Figure 2: The CURE trial. Cumulative hazard rates for the first primary
outcome (death from cardiovascular causes, nonfatal MI, or stroke) during
the first 30 days after randomization to clopidogrel or placebo. The results
demonstrate the early effect of clopidogrel. Reproduced with permission
from Yusuf S et al.5
the CURE trial support the long-term use of clopidogrel in
the management of ACS, including patients who are to be
medically managed.
Use of Thienopyridines in Percutaneous Coronary Intervention
Trials that have studied clopidogrel in the setting of PCI
have typically evaluated its effectiveness for the following
purposes: (1) preventing post-PCI-related complications;
(2) preventing coronary stent subacute thrombosis; and
(3) preventing thrombotic events in native coronary vessels.
In this section, we will review a number of clinical trials
in the settings of NSTEMI and STEMI, with a particular
focus on clinical trials that have established the value of
preprocedural and longer-term postprocedural antiplatelet
therapy.
Non-ST-Segment Elevation Myocardial Infarction
Establishing the value of preprocedure clopidogrel use:
Platelet activation can occur as a result of PCI in addition to
postprocedure atherosclerotic plaque rupture. A substudy
of 2,658 patients (21%) who underwent PCI in the CURE trial
a median of 10 days after enrollment was evaluated in the
Percutaneous Coronary Intervention in the Clopidogrel in
Unstable angina to prevent Recurrent Events (PCI-CURE)
trial.6 The use of clopidogrel in addition to pretreatment with
ASA in PCI-treated patients (n = 1, 313) was associated with
a significant reduction in the primary endpoint of cardiovas-
cular death, MI, or urgent target-vessel revascularization
within 30 days compared with the placebo group (relative
risk 0.70, p = 0.03) (Figure 3).6 Administration of clopido-
grel therapy for a mean period of 8 months after PCI was
also associated with a reduction in CV death, MI, or need
for any revascularization (p = 0.03). Thus, this trial estab-
lished that in patients with NSTEMI scheduled for PCI,
clopidogrel given prior to PCI and subsequent long-term
continuation may reduce both early and late major ischemic
cardiovascular events in this high-risk patient group. How-
ever, the duration of pretreatment with clopidogrel (median
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Figure 3: The PCI-CURE trial. Kaplan-Meier cumulative hazard rates for
primary outcome of cardiovascular death, MI, or urgent target-vessel
revascularization at 30 days after percutaneous coronary intervention and
clopidogrel. Reprinted with permission from Mehta SR et al.6
10 days) in PCI-CURE made the application of these results
to patients undergoing urgent PCI difficult.
Evidence to substantiate a standard 600 mg clopidogrel
loading dose prior to percutaneous coronary intervention:
Platelet function studies had suggested that treatment with
a higher loading dose of clopidogrel may be more effective
than a 300 mg loading dose.7–10 However, the Antiplatelet
therapy for Reduction of MYocardial Damage during
Angioplasty (ARMYDA-2) trial was the first randomized trial
to evaluate the clinical significance of the emerging practice
standard of high-dose clopidogrel pretreatment. A total of
255 patients scheduled to undergo PCI were randomized
to receive a 600 mg or 300 mg loading dose of clopidogrel
(in addition to ASA) administered 4–8 h prior to PCI. The
primary endpoint of the 30-day occurrence of death, MI, or
target-vessel revascularization occurred in 12% of those in
the conventional loading dose versus 4% of patients in the
high-loading dose group (p = 0.041) and this effect was due
entirely to protection from periprocedural MI.11
In a multivariable analysis, the high-loading regimen
was associated with a 50% risk reduction of periprocedural
MI (odds ratio [OR], 0.48; p = 0.044). A protective effect
was demonstrated in patients pretreated with statins (OR
0.28, p = 0.02); an additional risk reduction was identified
in patients who were taking statins prior to intervention
and received the 600 mg loading dose of clopidogrel (OR
0.20, p = 0.017). Pretreatment with a 600 mg loading dose
of clopidogrel 4–8 hours before PCI did not result in
postprocedural major bleeding or need for transfusion.11
This study did not include STEMI patients or NSTEMI
patients with elevated baseline CK-MB levels. Accord-
ingly, although higher-risk patients needing emergency
procedures would likely obtain a clinical benefit from a
high-loading regimen of clopidogrel, ARYMDA-2 does not
directly support the hypothesis that high-dose clopidogrel
can be used as a substitute for GP IIb/IIIa inhibitors in
patients with NSTEMI, but they could be used in patients
with stable coronary artery disease or who are troponin-
negative. However, the superior inhibition of platelet func-
tion and the results of ARMYDA-2 are factors that influenced
the change in practice pattern favoring higher clopidogrel
loading dosing that has been observed in recent years.
Assessing the optimal initiation and duration of dual
antiplatelet therapy: Clopidogrel for the Reduction of
Events During Observation (CREDO) was a randomized,
double-blind, placebo-controlled trial involving more than
2,100 patients that evaluated the benefit of clopidogrel
pretreatment (300 mg) and continuation with a maintenance
dose of 75 mg/day along with ASA for 12 months after PCI
(28 days of clopidogrel 75 mg/day, without a loading dose in
the control group). Patients who received the loading dose
and long-term clopidogrel demonstrated a 26.9% reduction
in the risk of stroke, MI, or death at 1 year (p = 0.02).12
The benefit of extended clopidogrel therapy was consistent
for each component of the composite endpoint. At 28
days post-PCI patients who received a loading dose of
clopidogrel at least 6 h prior to the procedure had a
38.6% reduction in the risk of death, MI, or urgent target-
vessel revascularization (p = 0.051). The CREDO trial is
significant because it was the first randomized trial to assess
the effect of a loading dose and duration of clopidogrel and
ASA in elective PCI; its findings support administering at
least 1 year of clopidogrel therapy post-PCI, and suggest a
reduction of events with a longer interval between loading-
dose administration and PCI.12
ST-segment Elevation Myocardial Infarction
Benefit of dual antiplatelet therapy in the setting of fib-
rinolysis: Pharmacologic reperfusion remains the most
common treatment for STEMI worldwide. Accordingly, a
trial was conducted to determine the value of clopidogrel in
patients with STEMI who received ASA and fibrinolytic ther-
apy. The Clopidogrel as Adjunctive Reperfusion Therapy-
Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI
28) trial evaluated 3,491 patients (age 18–75 years) present-
ing within 12 h of STEMI onset. Patients were randomly
assigned to receive clopidogrel with a 300 mg loading dose
or placebo; all patients also received ASA (with or without
heparin), and underwent angiography within 48–192 h after
initiating the study medication.
A composite primary endpoint (occluded infarct-related
artery on angiography [TIMI grade of 0 or 1], death,
or recurrent MI before angiography) was determined.
Significantly more placebo-treated patients (21.7%) reached
the composite endpoint (versus 15% in the clopidogrel
group; p<0.001). By 30 days, compared with placebo,
clopidogrel therapy had reduced the odds by 20% of reaching
the composite endpoint of death from CV causes, recurrent
MI, or recurrent ischemia leading to the need for urgent
revascularization (from 14.1% to 11.6%, p = 0.03); with
similar rates of major bleeding and intracranial hemorrhage
in both groups. The benefit found was consistent across
multiple subgroups, including those separated according to
the type of fibrinolytic or heparin used.13
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This trial established the effectiveness by which the
addition of clopidogrel to standard fibrinolytic therapy in
patients under 75 years of age can improve the patency
rate of the infarct-related artery and reduce ischemic
complications. The CLARITY-TIMI 28 trial was particularly
significant because clopidogrel’s benefit previously shown
in patients with documented atherosclerosis not associated
with ST-elevation was extended to patients with STEMI.
Benefit of dual antiplatelet therapy in the settingof percu-
taneous coronary intervention:A planned sub-analysis of the
CLARITY-TIMI 28 trial, the PCI-CLARITY-TIMI 28 trial was
conducted to determine the benefit of clopidogrel pretreat-
ment in patients with STEMI compared with clopidogrel
initiated at the time of PCI (Table 1).14 The composite pri-
mary endpoint of cardiovascular death, recurrent MI, or
stroke from the time of PCI to 30 days after randomiza-
tion was determined. Compared with no pretreatment, a
significant reduction in the primary composite endpoint fol-
lowing PCI through 30 days post-randomization was found
in patients pretreated with clopidogrel (3.6% versus 6.2%;
adjusted OR, 0.54; p = 0.008).
The clinical implications of these results are noteworthy;
for every 100 patients who undergo PCI and receive
clopidogrel pretreatment, approximately 2 MIs could be
prevented before PCI; additionally, 2 CV deaths, MIs, or
strokes could be prevented after PCI to 30 days. Only 23
patients would have to be treated with this strategy to
prevent 1 CV death, MI, or stroke.
Taken together with the data from PCI-CURE and
CREDO trials, PCI-CLARITY further supports the strategy
of clopidogrel pretreatment in patients undergoing PCI.
The broad spectrum of CAD risk for which clopidogrel
pretreatment has demonstrated consistent benefit should
encourage widespread incorporation of this strategy into
practice in patients who are not at excessive risk of
bleeding.
Establishing a mortality benefit with the use of clopido-
grel: ClOpidogrel and Metoprolol in Myocardial Infarction
Trial (COMMIT) was a large randomized, double-blind,
placebo-controlled trial (n = 45, 852) from 1,250 centers in
China involving patients presenting within 24 h of the symp-
tom onset of suspected STEMI. Patients were randomized to
receive clopidogrel 75 mg/days (no loading dose) or placebo
in combination with ASA 162 mg/d until hospital discharge
(or up to 28 days).15 The two co-primary outcomes were:
(1) a composite endpoint of death, reinfarction, or stroke;
and (2) all-cause mortality during the scheduled treatment
period.
COMMIT revealed the following:15
• A 9% significant proportional risk reduction (PRR)
(95% CI 3–14, p = 0.002) in the composite end-
point death, reinfarction, or stroke with clopidogrel
(Figure 4).
• A 7% significant PRR (95% CI, 1–13; p = 0.03) in
all-cause mortality in the ASA plus clopidogrel group
compared to the ASA plus placebo group; 1,726 (7.5%)
patients died in the clopidogrel group compared with
1,845 (8.1%) in the placebo group (Figure 5).
• No significant increase in the risk of bleeding during
the overall treatment period.
Although no loading dose was used in this study, the
findings of COMMIT are consistent with other trials adding
clopidogrel to ASA in patients with ACS; however, this trial
was large enough to show a mortality advantage with this
strategy in suspected STEMI patients without increasing
major bleeding.
An Evaluation of Dual Antiplatelet Therapy in High-Risk Patients
Given the benefit of dual antiplatelet therapy in patients
with ACS and in those undergoing PCI, evaluating this
approach as a strategy to improve outcomes in patients with
established disease and multiple risk factors was the next
logical step. The Clopidogrel for High Atherothrombotic
Risk and Ischemic Stabilization, Management, and Avoid-
ance (CHARISMA) trial randomized over 15,000 patients
with clinical evidence of cardiovascular disease (CVD) or
multiple risk factors to receive clopidogrel (75 mg daily) plus










Outcomes∗ before PCI 37 (4.0) 58 (6.2) 0.62 (0.40–0.95) 0.03
∗Myocardial infarction or stroke. Adapted with permission from Sabatine MS et al.10
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Placebo:
2,310 with event (10.1%)
Clopidogrel:
2,121 with event (9.2%)
9% (SE3) proportional risk




















































Figure 4: The ARMYDA-2 trial risk reduction in composite endpoint with
clopidogrel. Reproduced with permission from Chen ZM et al.11
low-dose ASA (75–162 mg daily) or placebo plus low-dose
ASA over 28 months.16 No statistically significant reduction
in the risk for the first occurrence of heart attack, stroke,
or cardiovascular death was observed in the clopidogrel
group versus the placebo group in this broad population of
patients.
Although CHARISMA was a negative trial with respect
to the primary efficacy endpoint in the overall population,
patients enrolled with established atherothrombotic disease
(also referred to as secondary prevention) who received
dual antiplatelet therapy, had a reduction in relative
risk of a recurrent MI, stroke, or cardiovascular death
compared to patients receiving placebo and ASA (6.9% with
clopidogrel versus 7.9% with placebo; RR, 0.88; 95% CI,
0.77–0.998; p = 0.046). A subsequent subgroup analysis of
patients enrolled with prior MI, prior ischemic stroke, or
symptomatic peripheral arterial disease showed a larger
possible benefit (7.3% with clopidogrel versus 8.8% with
placebo (hazard ratio, 0.83; 95% CI, 0.72–0.96; p = 0.01).
Future trials will need to confirm whether intensification of
chronic antithrombotic therapy beyond ASA alone in these
types of patients is truly useful.17
Additionally, asymptomatic patients in the Clopidogrel
for High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance (CHARISMA) trial (those with
multiple risk factors without documented cardiovascular
disease, such as diabetic patients) who received dual platelet
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Figure 5: The ARMYDA-2 trial risk reduction in all-cause mortality with
ASA plus placebo. Reproduced with permission from Chen ZM et al.11
bleeding.18 Therefore, dual antiplatelet therapy would not
be recommended in such patients, even though they are at
high risk for future ischemic events.16 It is unlikely that in a
primary prevention population more than ASA alone will be
useful in regards to antithrombotic therapy.
Evaluating the Role of Glycoprotein IIb/IIIa Antagonists in
Acute Coronary Syndrome Management
The GP IIb/IIIa receptors are members of the integrin family
of adhesion receptors. Once activated, these receptors
are able to bind adhesion proteins involved in platelet
aggregation, such as von Willebrand factor (vWF) and
fibrinogen. Inhibition of the platelet GP IIb/IIIa receptor
in the treatment of patients with ACS has been well-studied
with placebo-controlled trials completed in more than 30,000
patients.19 A meta-analysis on the use of GP IIb/IIIa
inhibitors in ACS demonstrated a 1% absolute benefit in
preventing thrombotic events compared with placebo (10.8%
versus 11.8%; p = 0.015). However, an absolute 1% increase
in major bleeding was also observed in GP IIb/IIIa-treated
patients, suggesting the need to identify certain subgroups
of patients with ACS who would be more likely to achieve
benefit from these compounds.20
Determining the benefit of glycoprotein IIb/IIIa recep-
tor antagonists in unstable angina and non-ST-segment
elevatedmyocardial infarction:The Platelet Receptor Inhibi-
tion in Ischemic Syndrome Management (PRISM) trial was
a randomized, double-blind study that assessed whether
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the nonpeptide GP IIb/IIIa receptor antagonist tirofiban,
when compared to unfractionated heparin, improved unsta-
ble clinical outcomes in 3,232 patients with UA already
receiving ASA. The occurrence of the composite endpoint
(death, MI, or refractory ischemia at 48 h) was lower in
the tirofiban group compared with unfractionated heparin
(UFH)-treated patients (3.8%, versus 5.6%, respectively; risk
ratio [RR], 0.67; p = 0.01).21 The PRISM- Patients Limited
by Unstable Signs and Symptoms (PLUS) study differed
from PRISM in its inclusion of a third treatment arm of
patients who received tirofiban and heparin and patients
with NSTEMI; a majority of patients were receiving UFH
at the time of randomization. The tirofiban-only arm was
discontinued early because of an increase in deaths at day
7. The frequency of the composite primary endpoint (death,
MI, or refractory ischemia) at 7 days was lower among the
patients who received tirofiban plus UFH than among those
who received UFH alone (12.9% versus 17.9%, respectively;
RR, 0.68; p = 0.004). At 30 days and at 6 months, the rate
of the composite endpoint in the tirofiban plus UFH group
was also lower than that in the UFH-only group (18.5% ver-
sus 22.3% at 30 days and 27.7% versus 32.1% at 6 months,
respectively; p = 0.03 and p = 0.02, respectively).22 The
PRISM and PRISM-PLUS trials established the initial value
of tirofiban in patients with UA and NSTEMI.
Evaluation of abciximab in acute coronary syndromes:
Atleast one randomized trial had demonstrated the ben-
eficial effects of GP IIb/IIIa inhibitors in patients with
refractory angina who underwent PCI23 and with tirofiban
in patients who underwent early revascularization22; how-
ever, no benefit was observed with the monoclonal antibody
and platelet GP IIb/IIIa receptor inhibitor abciximab after
30 days follow-up in the Global Utilization of Strategies to
Open Occluded Coronary Arteries Trial IV in Acute Coro-
nary Syndrome study (GUSTO IV-ACS) trial. This study
evaluated the effects of abciximab in NSTEMI patients
not scheduled for PTCA or CABG. Patients (n = 7, 800)
were randomized to receive either abciximab bolus and
24-hour infusion, abciximab bolus and 48-hour infusion,
or matching placebo.24 At 1 year, no survival benefit was
demonstrated to be associated with abciximab. Moreover, a
higher mortality rate was demonstrated in patients who were
troponin-negative or had elevated C-reactive protein levels
(p = 0.02 and p = 0.04, respectively).25 A meta-analysis of
6 large randomized trials of patients with ACS not sched-
uled to undergo early revascularization (including 30-day
death or MI results from GUSTO IV-ACS) found the largest
treatment benefit for patients with elevated troponin levels.20
Comparison of glycoprotein IIb/IIIa inhibitors during per-
cutaneous coronary intervention: Although a number of
trials conducted with GP IIb/IIIa inhibitors in the set-
ting of PCI had demonstrated reductions in the 30-day
composite endpoint of death, MI, and need for urgent
revascularization, a direct comparison between the relative
efficacy of abciximab and tirofiban had not been under-
taken. The Therapeutic Arthritis Research and Gastroin-
testinal Event Trial (TARGET) evaluated whether tirofiban
and abciximab provide similar efficacy outcomes among
patients undergoing non-emergent, stent-based PCI in an
international multicenter study in 4,809 patients randomly
assigned a bolus and infusion of tirofiban or abciximab. At
30 days, the composite primary endpoint of death, MI,
and urgent target-vessel revascularization had occurred
more frequently among tirofiban-treated patients compared
with those who received abciximab (7.6% versus 6.0%;
p = 0.038).26
Evaluating the necessity of abciximab with increased
clopidogrel loading doses: Evidence from PCI-CURE and
CREDO supports the practice of clopidogrel pretreatment to
prevent post-PCI complications. The Intracoronary Stenting
and Antithrombotic Regimen-Rapid Early Action for Coro-
nary Treatment (ISAR-REACT) trial which used a 600-mg
loading dose of clopidogrel, demonstrated good tolerability
and an extremely low occurrence of early complications.27
Given the recent shift in practice toward routine preproce-
dural use of clopidogrel 600 mg loading doses, the ISAR-
REACT-2 trial sought to determine whether the antiplatelet
effect provided by clopidogrel 600 mg loading doses obvi-
ates the need for GP IIb/IIIa inhibitors in high-risk patients
with ACS who undergo PCI.
The ISAR-REACT-2 trial was an international, multicen-
ter, double-blind, placebo-controlled trial that randomized
patients (n = 2, 022) with NSTEMI undergoing PCI to
receive either of the following: abciximab (0.25 mg/kg, fol-
lowed by a 0.125 µg/kg/m infusion for 12 hours, plus UFH)
or placebo plus UFH bolus, 140 U/kg). All patients received
clopidogrel 600 mg at least 2 hours prior to PCI and ASA 500
mg (oral or IV). Although the primary composite endpoint
(death, MI, or urgent target-vessel revascularization occur-
ring within 30 days after randomization) occurred in 8.9%
of abciximab-treated patients compared with 11.9% placebo-
treated patients (Figure 6A) (RR, 0.75; p = 0.03), there was
no statistically significant difference among patients with-
out elevated troponin levels (Figure 6B).28 There was a 29%
reduction in this endpoint in patients with elevated troponin
levels. These results indicate that the role of GP IIb/IIIa
antagonists with clopidogrel pretreatment appears to be in
higher-risk NSTEMI patients with elevated troponin levels.
Conclusion
The benefit of clopidogrel in ACS was established by
two landmark studies: CAPRIE and CURE. The use
of clopidogrel is now a key component of treatment
strategies used in the management of ACS, particularly
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Figure 6: (A) Kaplan-Meier Analysis of Cumulative Incidence of Death, Myocardial
Infarction, or Urgent Target Vessel Revascularization for Both Treatment Groups.
Reproduced with permission from Kastrati A et al.28 (B) Kaplan-Meier Analysis of
Cumulative Incidence of Death, Myocardial Infarction, or Urgent Target Vessel
Revascularization for Both Treatment Groups in the Subsets With and Without Elevated
Troponin Levels (>0.03 Mg/L). Reproduced with permission from Kastrati A et al.28
for patients who undergo PCI and require peri- and postpro-
cedural thrombus prevention. The role of the GP IIb/IIIa
antagonists in ACS is less well characterized, based on
the conflicting results of several studies evaluating different
patient populations. At this time, it appears that the use of GP
IIb/IIIa antagonists might be most beneficial in high-risk
patients with NSTEMI and elevated troponin levels who
are scheduled to undergo PCI. Novel antiplatelet
approaches and future clinical trials will char-
acterize further how to maximize the benefit of
antiplatelet therapy in the setting of ACS and
solve currently unmet clinical needs in this area,
determine what role these agents have in throm-
botic prevention, and which patient populations
will benefit the most.
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